MCMifen Chen

Mifen Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mifen Chen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Baoshan Cao

    Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

    1 shared publication
  • Chunlei Xu

    Department of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China

    1 shared publication
  • Dong Yan

    Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China

    1 shared publication
  • Fanghua Song

    Department of Internal Medicine, Baotou Cancer Hospital, Baotou, Inner Mongolia, China

    1 shared publication
  • Fei Yin

    Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China

    1 shared publication
  • Guangjie Han

    Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study

    by Mifen Chen, Zhenghang Wang, Zimin Liu, Ting Deng, Xiaodong Wang, Zhiwei Chang, Qi Zhang, Wenlei Yang, Ning Liu, Zhi Ji, et al.

    PURPOSE: To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers. METHODS: We retrospectively recruited patients with MSI/dMMR gastrointestinal cancer who received anti–PD-1/PD-L1 with or without chemotherapy and compared objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) of PD-1/PD-L1 inhibitor plus chemotherapy (chemo-anti–PD-1/PD-L1 group) and PD-1/PD-L1 inhibitor alone (anti–PD-1/PD-L1 group). Propensity score–based overlap weighting analysis was conducted to adjust the baseline covariable imbalance. Sensitivity analysis was performed to confirm the stability of the results by propensity score matching and multivariable Cox and logistic regression models. RESULTS: A total of 256 patients were eligible, with 68 and 188 receiving chemo-anti–PD-1/PD-L1 and anti–PD-1/PD-L1, respectively. The chemo-anti–PD-1/PD-L1 group showed significant improvements versus the anti–PD-1/PD-L1 group in ORR (61.8% v 38.8%; P = .001), DCR (92.6% v 74.5%; P = .002), PFS (median PFS [mPFS], not reached [NR] v 27.9 months; P = .004), and OS (median OS [mOS], NR v NR; P = .014). After overlap weighting, the improvements tended to be more significant with chemo-anti–PD-1/PD-L1 versus anti–PD-1/PD-L1 in ORR (62.5% v. 38.3%; P < .001), DCR (93.8% v 74.2%; P < .001), PFS (mPFS, NR v 26.0 months; P = .004), and OS (mOS, NR v NR; P = .010). These results were solidified through sensitivity analysis. CONCLUSION: Chemo-anti–PD-1/PD-L1 is superior to anti–PD-1/PD-L1 in MSI/dMMR gastrointestinal cancers with improved efficacy.